Search Results

Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.

NuCana Shares Plummet as Another Chemotherapy Replacement Fails Phase II

NuCana’s chemotherapy replacement has failed to improve progression-free survival in a Phase II test, sending the biotech’s shares down by 50%.

August 30, 2024

·

1 min read

·

Annalee Armstrong

Drug Development

NuCana on the Rocks After Key Asset Fails in Biliary Tract Cancer

Shares of NuCana have plunged more than 57% in premarket trading after the company announced its Phase III biliary tract cancer study. See more facts here.

March 3, 2022

·

3 min read

·

Alex Keown

Drug Development

Global Roundup: NuCana’s Biliary Tract Cancer Drug, Charles River, Noema and More

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

February 23, 2022

·

6 min read

·

Alex Keown

Drug Development

NuCana Stock Tumbles After Pancreatic Cancer Trial Halted Due to Futility

NuCana halted enrollment of patients in the Phase III ACELERATE trial on the advice of the study’s Independent Safety and Data Monitoring Committee.

August 21, 2019

·

2 min read

·

Alex Keown

NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer

NuCana plc (NASDAQ: NCNA) announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for orphan drug designation of Acelarin for the treatment of patients with biliary tract cancer

March 5, 2020

·

6 min read

Drug Development

NuCana Announces First Patients Dosed in Phase I Study of NUC-7738

NuCana plc (NASDAQ: NCNA) a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, today announced that the first patients have been dosed in the Phase I study of NUC-7738.

July 18, 2019

·

5 min read

Drug Development

NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

NuCana plc (NCNA) announced that the first patients have been dosed in its Phase III study of Acelarin (NUC-1031) plus cisplatin for the first-line treatment of patients with biliary tract cancer and that the study design is being presented at the ASCO-GI Conference in San Francisco.

January 28, 2020

·

6 min read

Drug Development

NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer

NuCana plc (NASDAQ: NCNA) announced the first patients have been enrolled in the NuTide:302 Study.

November 2, 2018

·

5 min read

Business

‘A Clever Bit of Chemistry': NuCana CEO Speaks on Company’s Biliary Tract Cancer Drug

If successful, the CEO told BioSpace in an exclusive interview that Acelarin will break the glass ceiling as the first FDA-approved treatment for biliary tract cancer.

November 19, 2019

·

3 min read

·

Alex Keown

Business

Citi Appointed As Depositary Bank For NuCana’s ADR Programme

October 3, 2017

·

2 min read